News
The day at a glance · 4 min read
Mood · Cautious
-15
Sentiment, −100 to +100
PAH Market Size (2025)
$8 billion
Big Pharma & Biotech
PAH Market CAGR (2022-2036)
6.7%
Big Pharma & Biotech
Amgen Olpasiran Trial Size
7,297 patients
Clinical Trials & Pipeline
Key driverEli Lilly's Mounjaro cardiovascular approval countered by Novartis late-stage trial failure clouding cardiovascular RNAi prospects
Daily briefHealthcare· Money365.Market AI ·

Lilly Expands Mounjaro Label; Novartis Trial Fails

FDA grants cardiovascular indication for Mounjaro while pelacarsen misses primary endpoint, dragging Amgen shares lower on mechanism concerns

Big Pharma & Biotech

Neutral
LLYJNJMRK
The FDA has approved Eli Lilly (LLY)'s Mounjaro to reduce the risk of heart attack or stroke in adults with type 2 diabetes, expanding the drug's indication beyond glycemic control and potentially strengthening physician adoption. The approval comes as Eli Lilly (LLY) has pursued an active acquisition strategy, with recent deals positioned to supplement the company's long-term growth beyond its GLP-1 franchise. Meanwhile, pharmaceutical stocks are rebounding as U.S. drug pricing clarity emerges, shifting focus to patent expirations and innovation-driven differentiation across the sector.
The pulmonary arterial hypertension market across the United States, EU4 countries, the United Kingdom, and Japan reached approximately USD 8 billion in 2025, with projections indicating compound annual growth of 6.7% from 2022 to 2036. Key players in the PAH market include United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson (JNJ), Merck (MRK), and Gossamer Bio, with the market expansion supported by rising prevalence and novel therapies entering late-stage development.

FDA & Regulation

Bullish
GILDMRKJNJLLY
Gilead Sciences (GILD) received FDA approval for Bixlenvo, a once-daily pill for adults with HIV whose infection is already suppressed to very low levels. The combination brings together bictegravir, a key component of Gilead (GILD)'s blockbuster Biktarvy, and lenacapavir, the foundation of the company's longer-term HIV strategy, adding another treatment to the firm's HIV portfolio. The approval provides Gilead (GILD) with a new growth path in the HIV market as it seeks to maintain its leadership position in antiretroviral therapy.
Emerging therapies for ulcerative colitis treatment reflect a growing market, with late-stage candidates including Obefazimod from Abivax, Tulisokibart from Merck (MRK), Olamkicept from Ferring Pharmaceuticals, Afimkibart from Roche, Icotrokinra from Johnson & Johnson (JNJ) and Protagonist Therapeutics, Duvakitug from Teva Pharmaceuticals and Sanofi, Zotemtegrast from Eli Lilly (LLY), Zasocitinib from Takeda, and XmAb942 from Xencor. Unmet needs in refractory patients, tolerability, access, adherence, and flare prevention are creating room for innovation in moderate-to-severe disease treatment.

Clinical Trials & Pipeline

Bearish

Tempus AI Cancer Dx Opportunity

$600 million
AMGNMRNAMRK
Novartis' pelacarsen cardiovascular outcomes study failed to cut cardiovascular events in its late-stage trial, clouding prospects for the drug and highlighting portfolio challenges for the Swiss pharmaceutical company. The failure has cast investor concern over whether Amgen (AMGN)'s competing drug olpasiran can deliver positive Phase III outcome data, with Amgen (AMGN) shares falling following the Novartis setback.
Novartis lowered the target biomarker without reducing events, meaning Amgen (AMGN)'s 7,297-patient heart trial must prove the mechanism can still deliver clinical benefit.
Personalized cancer vaccines are creating a diagnostics investment opportunity beyond Moderna (MRNA) and Merck (MRK), with tumor sequencing positioned at the center of the treatment paradigm. Analysts see a potential $600 million opportunity for Tempus AI as personalized oncology becomes an investable theme, driven by advances in genomic profiling and tailored immunotherapy approaches.

MedTech & Devices

Bullish
ISRG
Intuitive Surgical (ISRG)'s Ion platform is gaining momentum as a second growth engine, with rising procedures, a larger installed base, and global expansion fueling adoption of the bronchoscopy platform. The Ion system complements Intuitive Surgical (ISRG)'s da Vinci surgical robotics franchise and is positioning the company to capture market share in lung biopsy and early-stage cancer detection procedures. Device innovation continues to drive differentiation in the surgical robotics and diagnostics segments across the healthcare technology landscape.

Healthcare Market Overview

Neutral

Pfizer Dividend Yield

5.91%

UNH 20-Year Outperformance

1.51% annualized

UNH 20-Year Annual Return

10.72%
PFEUNH
The biotech sector staged one of its sharpest reversals in recent years, with the iShares Biotechnology ETF (IBB) beating the S&P 500 by 22 points over three months, raising questions about whether the trade still has momentum or if early gains have been exhausted.
Pfizer (PFE) continues to draw attention for its 5.91% dividend yield, though analysts note a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate investment case beyond income considerations.
UnitedHealth Group (UNH) has outperformed the market over the past 20 years by 1.51% on an annualized basis, producing an average annual return of 10.72%, demonstrating the long-term value creation potential in managed care.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy